吸入糖皮质激素治疗肺纤维化

The Effects of Glucocorticoid Inhalation on Pulmonary Fibrosis

目的 探讨吸入糖皮质激素治疗特发性肺间质纤维化 (IPF)的临床疗效。方法 慢性型IPF 30例 ,随机分为吸入组 10例 (普米克 ,每次 2喷 ,3次 /d)和口服组 2 0例 (强地松 1mg/kg .d- 1,2个月后减量维持 ) ,疗程 6个月。观察临床表现、肺功能改变及副作用。结果 2组病人临床表现、缓解时间、肺功能变化 ,差别无统计学意义 (P >0 0 5 ) ,吸入组副作用发生明显少于口服组 (χ2 =9 6 ,P <0 0 0 5 )。结论 吸入糖皮质激素(普米克 )代替口服及静脉用药治疗慢性型IPF副作用少且临床疗效确切 ,值得在临床推广使用。

Objective To investigate the clinical effects of glucocorticoid inhalation on idiopathic pulmonary fibrosis (IPF). Methods 30 chronic IPF patients were randomly divided into inhalation group (10 patients, Pulmicort, 2 puffs each time, three times each day) and oral group (20 patients, prednisone, 1mg·kg -1 ·d -1 , reduce the dosage 2 month later) . The clinical manifestation, pulmonary function and side effects were observed. Results There were no significant difference in the time of clinical manifestation and pulmonary function amelioration between the two groups. Conclusion Glucocorticoid inhalation was effective in the treatment of chronic IPF, and had few side effects. It is worth highly recommending for clinical using.